AtriCure, Inc. (NASDAQ:ATRC) Insider Sells $36,135.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $24.09, for a total transaction of $36,135.00. Following the completion of the transaction, the insider now owns 71,284 shares of the company’s stock, valued at approximately $1,717,231.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

AtriCure Stock Down 6.0 %

Shares of NASDAQ:ATRC opened at $20.89 on Monday. The company has a market capitalization of $994.16 million, a P/E ratio of -26.11 and a beta of 1.41. The stock’s fifty day simple moving average is $28.81 and its 200-day simple moving average is $33.09. AtriCure, Inc. has a 52-week low of $20.19 and a 52-week high of $59.61. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $108.90 million for the quarter, compared to analyst estimates of $106.86 million. AtriCure had a negative return on equity of 7.82% and a negative net margin of 8.98%. AtriCure’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) earnings per share. As a group, equities research analysts forecast that AtriCure, Inc. will post -0.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AtriCure

Several large investors have recently added to or reduced their stakes in ATRC. Norges Bank purchased a new position in shares of AtriCure during the 4th quarter worth about $9,254,000. TimesSquare Capital Management LLC grew its stake in shares of AtriCure by 39.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 904,835 shares of the medical device company’s stock valued at $39,632,000 after buying an additional 254,655 shares during the period. Wasatch Advisors LP increased its holdings in shares of AtriCure by 38.6% during the 1st quarter. Wasatch Advisors LP now owns 720,677 shares of the medical device company’s stock worth $21,923,000 after buying an additional 200,799 shares during the last quarter. Fiera Capital Corp raised its position in shares of AtriCure by 28.2% in the 4th quarter. Fiera Capital Corp now owns 881,826 shares of the medical device company’s stock worth $31,472,000 after buying an additional 193,769 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in AtriCure by 71.6% in the first quarter. Assenagon Asset Management S.A. now owns 444,801 shares of the medical device company’s stock valued at $13,531,000 after acquiring an additional 185,632 shares during the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on ATRC shares. JPMorgan Chase & Co. dropped their target price on shares of AtriCure from $42.00 to $34.00 and set an “overweight” rating for the company in a report on Thursday. Stifel Nicolaus dropped their price objective on AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Oppenheimer raised AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a report on Tuesday, April 23rd. UBS Group upped their target price on AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Canaccord Genuity Group dropped their price target on AtriCure from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and an average price target of $49.78.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.